中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
15期
1494-1496
,共3页
康莱特%非小细胞肺癌%吉西他滨%顺铂%临床疗效
康萊特%非小細胞肺癌%吉西他濱%順鉑%臨床療效
강래특%비소세포폐암%길서타빈%순박%림상료효
Kanglaite%non-small cell lung cancer%gemcitabine%cisplatinum%clinical efficacy
目的：评价康莱特联合吉西他滨＋顺铂方案治疗晚期非小细胞肺癌的临床疗效和安全性及其对T淋巴细胞亚群的影响。方法将69例晚期非小细胞肺癌患者随机分为对照组36例和试验组33例。对照组给予1000 mg · m－2吉西他滨，第1，8天＋80 mg· m－2顺铂，第2天，3周为1个周期，连续化疗2个周期；试验组在对照组的基础上，联合静脉点滴康莱特200 mL，10 d为1个周期，随化疗连续应用2个周期。2个化疗周期结束后，进行2组的临床疗效、T淋巴细胞亚群（CD3，CD4和CD8）活性及不良反应评价。结果治疗后，对照组客观有效率为22.22％略低于试验组27.27％（ P＞0.05）。治疗后，试验组T淋巴细胞亚群CD3、CD4和CD8值显著高于对照组（ P＜0.05）。2组患者主要不良反应为骨髓抑制和胃肠道反应，试验组Ⅲ～Ⅳ级不良反应发生率显著低于对照组（P＜0.05）。结论康莱特联合西他滨和顺铂治疗晚期非小细胞肺癌可提高患者T淋巴细胞亚群比例，降低化疗相关不良反应发生率。
目的：評價康萊特聯閤吉西他濱＋順鉑方案治療晚期非小細胞肺癌的臨床療效和安全性及其對T淋巴細胞亞群的影響。方法將69例晚期非小細胞肺癌患者隨機分為對照組36例和試驗組33例。對照組給予1000 mg · m－2吉西他濱，第1，8天＋80 mg· m－2順鉑，第2天，3週為1箇週期，連續化療2箇週期；試驗組在對照組的基礎上，聯閤靜脈點滴康萊特200 mL，10 d為1箇週期，隨化療連續應用2箇週期。2箇化療週期結束後，進行2組的臨床療效、T淋巴細胞亞群（CD3，CD4和CD8）活性及不良反應評價。結果治療後，對照組客觀有效率為22.22％略低于試驗組27.27％（ P＞0.05）。治療後，試驗組T淋巴細胞亞群CD3、CD4和CD8值顯著高于對照組（ P＜0.05）。2組患者主要不良反應為骨髓抑製和胃腸道反應，試驗組Ⅲ～Ⅳ級不良反應髮生率顯著低于對照組（P＜0.05）。結論康萊特聯閤西他濱和順鉑治療晚期非小細胞肺癌可提高患者T淋巴細胞亞群比例，降低化療相關不良反應髮生率。
목적：평개강래특연합길서타빈＋순박방안치료만기비소세포폐암적림상료효화안전성급기대T림파세포아군적영향。방법장69례만기비소세포폐암환자수궤분위대조조36례화시험조33례。대조조급여1000 mg · m－2길서타빈，제1，8천＋80 mg· m－2순박，제2천，3주위1개주기，련속화료2개주기；시험조재대조조적기출상，연합정맥점적강래특200 mL，10 d위1개주기，수화료련속응용2개주기。2개화료주기결속후，진행2조적림상료효、T림파세포아군（CD3，CD4화CD8）활성급불량반응평개。결과치료후，대조조객관유효솔위22.22％략저우시험조27.27％（ P＞0.05）。치료후，시험조T림파세포아군CD3、CD4화CD8치현저고우대조조（ P＜0.05）。2조환자주요불량반응위골수억제화위장도반응，시험조Ⅲ～Ⅳ급불량반응발생솔현저저우대조조（P＜0.05）。결론강래특연합서타빈화순박치료만기비소세포폐암가제고환자T림파세포아군비례，강저화료상관불량반응발생솔。
Objective To evaluate the clinical efficacy, safety and affection for T lymph cell subgroup by gemcitabine and cisplatinum chemotherapy combined with Kanglait in the treatment of advanced non-small cell lung carcinoma.Methods Sixty -nine non -small lung cancer patients were included in this study and randomly divided into control group ( n=36 ) and treatment group ( n=33 ).The patients in the control group were treated with gemcitabine 1000 mg · m-2 , day 1, 8 +cisplatinum 80 mg· m-2 , day 2, three weeks per cycle with 2 cycles treatment.Patients in the treatment group were treated with basis on control group, plus Kanglaite injection 200 mL qd ×10 days per cycle for 2 cycles with the chemotherapy regimen.After 2 cycles chemotherapy treatment, the clinical efficacy, chemotherapy related toxicity and T lymph cell subgroup were analyzed between the two groups.Results The objective response rate were 22.22%and 27.27%for the control and treatment group respectively without statistical difference ( P>0.05).The T lymph cell subgroup in treatment group was signifi-cant higher than in the control group ( P <0.05 ) .The main chemotherapy related toxicity were bone marrow depression and gastrointestinal reaction with no statistical difference between the two groups ( P>0.05).Conclusion Gemcitabine+cisplatinum chemotherapy combined with Kanglait can elevate the T lymph cell subgroup and decrease the chemotherapy toxicity.
